Physician profile
Denise Tonner
NPI 1821171372
$3,605.49
in general payments reported to CMS, 2019-2025
26 companies · $45.63 in 2025
The $45.63 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $543 · 2021: $972 · 2022: $641 · 2023: $208 · 2024: $83.71 · 2025: $45.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $337.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $673.82 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $512.52 | 2019-2022 | |
| Novo Nordisk INC | $509.03 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $454.79 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $344.33 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Bayer Healthcare Pharmaceuticals INC. | $231.27 | 2021-2023 | |
| Dexcom, INC. | $142.74 | 2021-2024 | Dexcom G6 Transmitter |
| Radius Health, INC. | $114.54 | 2019-2021 | |
| Insulet Corporation | $102.94 | 2019-2022 | |
| Abbott Laboratories | $90.86 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $58.94 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $55.89 | 2019-2020 | |
| Amgen INC. | $50.29 | 2019 | |
| Amarin Pharma, INC. | $37.27 | 2019-2020 | |
| Medtronic, INC. | $35.03 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $24.46 | 2019 | |
| Merck Sharp & Dohme LLC | $23.19 | 2019 | |
| Horizon Therapeutics Plc | $22.21 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.88 | 2023 | Gvoke Hypopen |
| Endo Pharmaceuticals INC. | $18.43 | 2022 | |
| Abbvie INC. | $16.13 | 2019 | |
| Pfizer INC. | $15.74 | 2023 | |
| Medtronic Minimed, INC. | $13.33 | 2019 | |
| Tolmar, INC. | $12.98 | 2023 | |
| Clarus Therapeutics INC. | $12.97 | 2021 | |
| Valeritas, INC. | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Tonner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.